Table 1.
Association between clinicopathological features and survival of gastric cancer.
| Variables | Patients, n = 909 | Deaths, n = 418 | MST (Months) | log-Rank p | HR (95% CI) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age (years) | |||||||||||
| ≤60 | 429 | 195 | 97 | 0.354 | 1.000 | ||||||
| >60 | 480 | 223 | 62 | 1.095 (0.903–1.327) | |||||||
| Sex | |||||||||||
| Male | 700 | 320 | 74 | 0.57 | 1.000 | ||||||
| Female | 209 | 98 | 67 | 1.067 (0.851–1.338) | |||||||
| Tumor size | |||||||||||
| ≤5 cm | 564 | 236 | 74 | <0.001 | 1.000 | ||||||
| >5 cm | 345 | 182 | 51 | 1.409 (1.616–1.710) | |||||||
| Location | |||||||||||
| Non-Cardia | 601 | 280 | 70 | 0.371 | 1.000 | ||||||
| Cardia | 308 | 138 | 77 | 0.912 (0.744–1.118) | |||||||
| Histological types | |||||||||||
| Intestinal | 387 | 149 | 77 | <0.001 | 1.000 | ||||||
| Diffuse | 518 | 266 | 52 | 1.453 (1.189–1.776) | |||||||
| Others | 4 | 3 | 11 | 2.732 (0.871–8.571) | |||||||
| Differentiation a | |||||||||||
| Well-to-moderate | 297 | 125 | 80 | 0.49 | 1.000 | ||||||
| Poorly | 472 | 228 | 62 | 1.158 (0.931–1.441) | |||||||
| Mucinous/signet-ring cell | 65 | 32 | 62 | 1.202 (0.815–1.772) | |||||||
| Others | 75 | 33 | 67 | 0.986 (0.671–1.448) | |||||||
| Depth of invasion b | |||||||||||
| T1 | 177 | 57 | N/A1 | <0.001 | 1.000 | ||||||
| T2 | 130 | 56 | 78 | 1.452(1.004–2.101) | |||||||
| T3 | 6 | 3 | 70 | 1.427(0.447–4.559) | |||||||
| T4 | 578 | 291 | 52 | 1.839(1.383–2.446) | |||||||
| Lymph node metastasis c | |||||||||||
| N0 | 359 | 128 | N/A1 | <0.001 | 1.000 | ||||||
| N1/N2/N3 | 529 | 277 | 48 | 1.731 (1.403–2.136) | |||||||
| Distant metastasis | |||||||||||
| M0 | 891 | 407 | 74 | 0.296 | 1.000 | ||||||
| M1 | 16 | 9 | 40 | 1.417 (0.732–2.743) | |||||||
| TNM stage | |||||||||||
| I | 239 | 80 | N/A1 | <0.001 | 1.000 | ||||||
| II | 195 | 77 | N/A1 | 1.241 (0.907–1.698) | |||||||
| III | 447 | 244 | 41 | 1.993 (1.547–2.568) | |||||||
| IV | 22 | 11 | 47 | 1.823 (0.970–3.424) | |||||||
| Chemotherapy | |||||||||||
| No | 618 | 293 | 62 | 0.344 | 1.000 | ||||||
| Yes | 291 | 125 | 98 | 0.904 (0.734–1.115) | |||||||
| Chemotherapy regimes | |||||||||||
| l-OHP | 109 | 38 | 60 | 0.082 | 1.000 | ||||||
| DDP | 179 | 89 | 51 | 1.398 (0.954–2.048) | |||||||
| Smoking | |||||||||||
| Non-smoker | 833 | 386 | 67 | 0.432 | 1.000 | ||||||
| Smoker | 76 | 32 | 97 | 0.866 (0.604–1.243) | |||||||
| Drinking | |||||||||||
| Non-drinker | 850 | 389 | 70 | 0.691 | 1.000 | ||||||
| Drinker | 59 | 29 | 63 | 1.079 (0.740–1.574) |
Abbreviations: MST, median survival time; HR, hazard ratio; CI, confidence interval; TNM, Tumor, Node and Metastasis; l-OHP, oxaliplatin; DDP, cisplatin. a Partial data were not available, and statistics were based on available data; b The information about the depth of invasion was not available for two patients; invaded depth of tumor was classified according to the criteria of American Joint Commission on Cancer (AJCC) 7th; c Lymph nodes were staged according to tumor-node-metastasis classification of the 7th edition of AJCC in which the number of lymph nodes with a metastasis of 1, 2, 3, 6 and 7 were classified as N1, N2 and N3, respectively. N/A1, Mean the median survival time could not be measured.